(以下内容从山西证券《创新药动态更新:D-1/VEGF/CTLA-4三抗CS2009:剂量爬坡耐受性良好,冷肿瘤及PD-(L)1经治患者中观察到抗肿瘤活性》研报附件原文摘录)药物点评:CS2009是基石药业自研的PD-1/VEGF/CTLA-4三特异性抗体。CS2009具有单价PD-1和CTLA-4结合臂以及双价VEGFA结合臂,通过阻断PD-1/CTLA-4、激活T细胞及中和VEGFA,实现...
Source Link(以下内容从山西证券《创新药动态更新:D-1/VEGF/CTLA-4三抗CS2009:剂量爬坡耐受性良好,冷肿瘤及PD-(L)1经治患者中观察到抗肿瘤活性》研报附件原文摘录)药物点评:CS2009是基石药业自研的PD-1/VEGF/CTLA-4三特异性抗体。CS2009具有单价PD-1和CTLA-4结合臂以及双价VEGFA结合臂,通过阻断PD-1/CTLA-4、激活T细胞及中和VEGFA,实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.